Atara Biotherapeutics, Inc. (0HIY.L)

USD 10.43

(-0.02%)

Market Cap (In USD)

62.38 Million

Revenue (In USD)

8.57 Million

Net Income (In USD)

-276.12 Million

Avg. Volume

52.1 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.1996-10.6037
PE
-
EPS
-
Beta Value
0.495
ISIN
US0465131078
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Dr. Anhco Nguyen Ph.D.
Employee Count
-
Website
https://www.atarabio.com
Ipo Date
2018-01-29
Details
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.